Reuters logo
21 天前
BRIEF-Alkermes announces positive preliminary topline results
2017年6月29日 / 晚上8点17分 / 21 天前

BRIEF-Alkermes announces positive preliminary topline results

2 分钟阅读

June 29 (Reuters) - Alkermes Plc:

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

* Alkermes announces positive preliminary topline results from phase 3 antipsychotic efficacy study of ALKS 3831 for treatment of schizophrenia

* Alkermes Plc - study met prespecified primary endpoint

* Alkermes - ALKS 3831 demonstrating statistically significant reductions from baseline in positive and negative syndrome scale scores versus placebo

* Alkermes Plc - study also met its key secondary endpoint

* Alkermes Plc - study met prespecified primary endpoint, with ALKS 3831

* Alkermes - enlighten-2, six-month phase 3 study evaluating weight gain profile of olanzapine compared to ALKS 3831, is ongoing with data expected in 2018

* Alkermes Plc - ALKS 3831 demonstrated statistically significant reductions from baseline in positive and negative syndrome scale scores compared to placebo Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below